Description: Kopran Limited, an integrated pharmaceutical company, manufactures and sells active pharmaceutical ingredients and finished dosage forms in India and internationally. The company offers finished dosage forms, including tablets, capsules, dry powder, suspension, and injectable in various therapeutic areas comprising cardiovascular, gastrointestinal, pain management, oncology, anti-allergic, central nervous system, erectile dysfunction, and others, as well as antibiotics, anti-diabetic, respiratory, anthelmentics, antiprotozoals, and antipeptic ulcer and gut. It also provides active pharmaceutical ingredients in the categories of anti-hypertensive, macrolide, neuromodulator, sterile cephalosporins, carbapenems, anti-acne, anti-ulcerant, anti-depressent, anti-infective, urological, and anti-thrombotic. The company was incorporated in 1958 and is headquartered in Mumbai, India.
Home Page: www.kopran.com
Parijat House
Mumbai,
400018
India
Phone:
91 22 4366 1111
Officers
| Name | Title |
|---|---|
| Mr. Surendra Shrikrishna Somani | Exec. Vice Chairman |
| Mr. Basant Kumar Soni | Chief Financial Officer |
| Mr. Sunil Sodhani | Company Sec. & Compliance Officer |
| Mr. Ajit Jain | Chief Operating Officer |
| Chandra M. Singhi | Director |
| Ahren A. Rodrigues | Company Sec. of Kopran Laboratories Limited |
| Ms. Vandana Somani | Director |
| Rakesh Doshi | Director |
| K. B. Shetty | Chief Financial Officer of Kopran Laboratories Limited |
Exchange: BSE
Country: IN : India
Currency: Indian Rupee (INR)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 12.8711 |
| Price-to-Book MRQ: | 2.4493 |
| Price-to-Sales TTM: | 1.2653 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 0 |